PMID- 24243925
OWN - NLM
STAT- MEDLINE
DCOM- 20150219
LR  - 20220409
IS  - 1468-2060 (Electronic)
IS  - 0003-4967 (Linking)
VI  - 74
IP  - 1
DP  - 2015 Jan
TI  - Damage in the anca-associated vasculitides: long-term data from the European 
      vasculitis study group (EUVAS) therapeutic trials.
PG  - 177-84
LID - 10.1136/annrheumdis-2013-203927 [doi]
AB  - OBJECTIVES: To describe short-term (up to 12 months) and long-term (up to 
      7 years) damage in patients with newly diagnosed antineutrophil-cytoplasm 
      antibody-associated vasculitis (AAV). METHODS: Data were combined from six 
      European Vasculitis Study group trials (n=735). Long-term follow-up (LTFU) data 
      available for patients from four trials (n=535). Damage accrued was quantified by 
      the Vasculitis Damage Index (VDI). Sixteen damage items were defined a priori as 
      being potentially treatment-related. RESULTS: VDI data were available for 629 of 
      735 patients (85.6%) at baseline, at which time 217/629 (34.5%) had >/=1 item of 
      damage and 32 (5.1%) >/=5 items, reflecting disease manifestations prior to 
      diagnosis and trial enrolment. LTFU data were available for 467/535 (87.3%) at a 
      mean of 7.3 years postdiagnosis. 302/535 patients (56.4%) had VDI data at LTFU, 
      with 104/302 (34.4%) having >/=5 items and only 24 (7.9%) no items of damage. At 
      6 months and LTFU, the most frequent items were proteinuria, impaired glomerular 
      filtration rate, hypertension, nasal crusting, hearing loss and peripheral 
      neuropathy. The frequency of damage, including potentially treatment-related 
      damage, rose over time (p<0.01). At LTFU, the most commonly reported items of 
      treatment-related damage were hypertension (41.5%; 95% CI 35.6 to 47.4%), 
      osteoporosis (14.1%; 9.9 to 18.2%), malignancy (12.6%; 8.6 to 16.6%), and 
      diabetes (10.4%; 6.7 to 14.0%). CONCLUSIONS: In AAV, renal, otolaryngological and 
      treatment-related (cardiovascular, disease, diabetes, osteoporosis and 
      malignancy) damage increases over time, with around one-third of patients having 
      >/=5 items of damage at a mean of 7 years postdiagnosis.
CI  - Published by the BMJ Publishing Group Limited. For permission to use (where not 
      already granted under a licence) please go to 
      http://group.bmj.com/group/rights-licensing/permissions.
FAU - Robson, Joanna
AU  - Robson J
AD  - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science 
      (NDORMs), University of Oxford, Oxford, USA Rheumatology Department, Nuffield 
      Orthopaedic Centre, Oxford, UK.
FAU - Doll, Helen
AU  - Doll H
AD  - Department of Population Health, Norwich Medical School, Faculty of Medicine and 
      Health Sciences, University of East Anglia, Norwich, UK.
FAU - Suppiah, Ravi
AU  - Suppiah R
AD  - Department of Rheumatology, Auckland District Health Board, Auckland, New 
      Zealand.
FAU - Flossmann, Oliver
AU  - Flossmann O
AD  - Renal Department, Royal Berkshire NHS Foundation Trust, Reading, UK.
FAU - Harper, Lorraine
AU  - Harper L
AD  - School of Immunity and Infection, Centre for Translational Inflammation Research, 
      University of Birmingham, Birmingham, UK.
FAU - Hoglund, Peter
AU  - Hoglund P
AD  - Competence Centre for Clinical Research, Skane University Hospital, Lund, Sweden.
FAU - Jayne, David
AU  - Jayne D
AD  - Renal Department, Addenbrooke's Hospital, Cambridge, UK.
FAU - Mahr, Alfred
AU  - Mahr A
AD  - Department of Internal Medicine, Hospital Saint-Louis, Paris, France.
FAU - Westman, Kerstin
AU  - Westman K
AD  - Nephrology and Transplantation, Skane University Hospital Malmo, Lund University, 
      Malmo, Sweden.
FAU - Luqmani, Raashid
AU  - Luqmani R
AD  - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science 
      (NDORMs), University of Oxford, Oxford, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131115
PL  - England
TA  - Ann Rheum Dis
JT  - Annals of the rheumatic diseases
JID - 0372355
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/complications/drug 
      therapy
MH  - Diabetes Mellitus/etiology
MH  - Disease Progression
MH  - Europe
MH  - Female
MH  - Glomerular Filtration Rate
MH  - Granulomatosis with Polyangiitis/*complications/drug therapy
MH  - Hearing Loss/*etiology
MH  - Humans
MH  - Hypertension/*etiology
MH  - Immunosuppressive Agents/adverse effects
MH  - Male
MH  - Microscopic Polyangiitis/*complications/drug therapy
MH  - Middle Aged
MH  - Nasal Obstruction/*etiology
MH  - Neoplasms/etiology
MH  - Osteoporosis/etiology
MH  - Peripheral Nervous System Diseases/*etiology
MH  - Proteinuria/*etiology
MH  - Severity of Illness Index
OTO - NOTNLM
OT  - Disease Activity
OT  - Epidemiology
OT  - Granulomatosis with polyangiitis
OT  - Outcomes research
OT  - Treatment
EDAT- 2013/11/19 06:00
MHDA- 2015/02/20 06:00
CRDT- 2013/11/19 06:00
PHST- 2013/11/19 06:00 [entrez]
PHST- 2013/11/19 06:00 [pubmed]
PHST- 2015/02/20 06:00 [medline]
AID - annrheumdis-2013-203927 [pii]
AID - 10.1136/annrheumdis-2013-203927 [doi]
PST - ppublish
SO  - Ann Rheum Dis. 2015 Jan;74(1):177-84. doi: 10.1136/annrheumdis-2013-203927. Epub 
      2013 Nov 15.